| Name | Title | Contact Details |
|---|
Starr Insurance is a prominent part of Starr Companies, a global insurance and investment organization founded in 1919 by Cornelius Vander Starr. Initially established as the first American-owned insurance agency in Shanghai, the company has grown to operate across six continents, becoming a significant player in the insurance industry. Starr Insurance offers a diverse range of products and services, including commercial property and casualty insurance, as well as specialty coverages such as aviation, marine, energy, and excess casualty insurance. The company serves a wide array of clients, including leading businesses in sectors like construction, maritime, energy, and aerospace. With its extensive global presence, Starr Insurance is well-equipped to provide comprehensive insurance solutions tailored to the needs of businesses worldwide.
PremiumIQ helps insurance companies increase premiums, reduce losses and engage customers with advanced data solutions. We assist data analytics teams in achieving faster results, fostering trust, and effectively managing costs. Were data specialists focused singularly on helping insurance clients implement next generation applications, architectures, and operating models.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Grant Thornton una de las firmas líderes a nivel mundial de servicios profesionales de Auditoría, Consultoría de Negocio, Tecnología e Innovación y Asesoramiento Fiscal, Legal, Financiero, Laboral y Outsourcing. Pertenecemos a una de las organizaciones y red líderes en servicios profesionales en todo el mundo, Grant Thornton International, con más de 73.000 profesionales presentes en más de 147 mercados. En España contamos con un equipo multidisciplinar, transversal, con experiencia y visión empresarial, que da servicio a más de 4.000 clientes en 10 oficinas repartidas por el territorio nacional: Madrid, Barcelona, Bilbao, Castellón, Las Palmas, Murcia, Valencia, Pamplona y Zaragoza.